Drug
Olorofim clinical trials
Also written F901318.
- studies test it
- 19
- open now
- 1
- in phase 3
- 1
- first study started
- 2014
Keep track of what changes. Save the olorofim studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2017 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2018 | 1 |
| 2019 | 4 |
| 2021 | 1 |
| 2022 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 16
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 1
Often tested with
Tested in the same studies.
Posaconazole (2) · Liposomal amphotericin B (1) · Amphotericin B (1) · Itraconazole (1) · Rifampin (1) · Fluconazole (1) · Midazolam (1) · Caspofungin (1)
Studies
Open first, then newest update. How each study uses olorofim is read from its arms, and is right about nine times in ten.
Testing it · 19
- Olorofim in Early Coccidioidal MeningitisRecruitingPhase 2Fariba DonovanNCT07385638Written as olorofim
- Olorofim Aspergillus Infection StudyCompletedPhase 3F2G LtdNCT05101187Written as Olorofim
- Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment OptionsCompletedPhase 2F2G Biotech GmbHNCT03583164Written as Olorofim
- A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal ImpairmentCompletedPhase 1F2G Biotech GmbHNCT05200286Written as Olorofim
- A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic ImpairmentCompletedPhase 1F2G Biotech GmbHNCT04752540Written as Olorofim
- A Biopharmaceutics Study to Assess the Pharmacokinetics of Single Oral and IV Doses of OlorofimCompletedPhase 1F2G Biotech GmbHNCT04207957Written as Olorofim
- Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon OlorofimCompletedPhase 1F2G Biotech GmbHNCT04171739Written as Olorofim
- Absorption, Metabolism and Excretion of 14C-olorofim in ManCompletedPhase 1F2G Biotech GmbHNCT04039880Written as Olorofim
- Radiolabelled IV and Oral Metabolism Study of F901318WithdrawnPhase 1F2G Biotech GmbHNCT02912026Written as IV F901318
- Assessment of Varying Oral Dosing Regimens for F901318 in Healthy SubjectsCompletedPhase 1F2G Biotech GmbHNCT03340597Written as F901318
- Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml LeukaemiaWithdrawnPhase 1/2F2G Biotech GmbHNCT03036046Written as F901318 with posaconazole
- Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML PatientsWithdrawnPhase 1/2F2G Biotech GmbHNCT02856178Written as F901318
- Pharmacokinetics of IV FormulationWithdrawnPhase 1F2G Biotech GmbHNCT03076905Written as F901318
- Drug/Drug Interactions With F901318WithdrawnPhase 1F2G Biotech GmbHNCT03095547Written as F901318
- Study of Potential for Interaction of Fluconazole With F901318CompletedPhase 1F2G Biotech GmbHNCT02730442Written as F901318
- Evaluation of Immediate Release TabletCompletedPhase 1F2G Biotech GmbHNCT02808741Written as F901318 IR
- F901318 Multiple Ascending Dose StudyCompletedPhase 1F2G Biotech GmbHNCT02342574Written as F901318
- Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a ProbeCompletedPhase 1F2G Biotech GmbHNCT02680808Written as Midazolam with F901318
- F901318 Single Ascending Dose Study in Healthy Male VolunteersCompletedPhase 1F2G Biotech GmbHNCT02142153Written as F901318
As the comparator · 1 — what is tested is compared with olorofim
Codes
What other systems call olorofim · ClinicalTrials.gg INT000920
- MeSH (NLM) C000626907olorofimConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) T34SH2H9HIOLOROFIMConfirmed FDA, NLM, Wikidata
- Wikidata Q27896127olorofimConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170250OlorofimOne source FDA
- DrugBank DB15245One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626907 | olorofim | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | T34SH2H9HI | OLOROFIM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27896127 | olorofim | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170250 | Olorofim | One source FDA |
| DrugBank | DB15245 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.